Key result
18FDG-PET complements tissue biopsy in soft tissue sarcomas by aiding staging, grading, and prognosis.
PET scanning, particularly with 18FDG, complements tissue biopsy by providing functional imaging that aids in differentiating, grading, staging, and determining the prognosis of soft tissue sarcomas.
May support 18FDG-PET adjunctively in sarcoma care; leaves open prospective validation before routine use.
The purpose of this review is to underscore the value of positron emission tomography (PET) in the management of patients with soft tissue sarcomas. Although the most essential step in the diagnostic evaluation of soft tissue sarcomas is tumor biopsy, functional imaging techniques is growing and becoming more popular than before. PET scan traces molecular and cellular activities of normal and tumor cells through the use of radiotracers that engage in cell metabolism. The most important and widely used tracer is fluorodeoxyglucose (18FDG). PET scan usefulness is not limited to its ability to differentiate benign from malignant lesions. The scan can detect intralesional morphologic variation which is especially true in soft tissue sarcomas, it can predict tumor grade, and it is of value in staging, restaging and prognosis. As for the time, PET is not meant to replace tissue biopsy but rather complement the biopsy to better understand the biological behavior of soft tissue sarcomas.
No takes yet. Share an insight, caveat, or question.
Israel-Mardirosian et al. (2003) conducted a review in Soft tissue sarcomas. Positron emission tomography (PET) was evaluated. Positron emission tomography (PET) using 18FDG complements tissue biopsy in managing soft tissue sarcomas by differentiating lesions, predicting tumor grade, and aiding in staging and prognosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: